Scantox, together with its majority owner Impilo, has acquired Gentronix Ltd, a UK based GLP-compliant genetic toxicology Contract Research Organization (“CRO”).
Gentronix, now integrated into the Scantox Group, is well recognised for its high-quality genetic toxicology services and strong scientific engagement, with an undisputed track record of serving a loyal and broad global customer base. With the acquisition of Gentronix, Scantox’s service platform expands significantly to meet client demands as a market-leading CRO to support pre-IND enabling studies.
For 25 years, Gentronix has provided genetic toxicology solutions to the global pharma, biotech and agrichem industries; helping clients to optimise their development programs by enabling early identification of genotoxic compounds and supporting late-stage development phases with GLP studies. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity assays and services, not least the OECD 488 Big Blue® Transgenic Rodent Mutation assay, as one of only three global providers. Further, Gentronix has expertise and services within ocular and skin toxicology endpoints.
PMSI provided VCDD to support the transaction.
Matt Tate, Managing Director at Gentronix, commented: “It was a pleasure to work with Gareth and the team at PMSI, who supported us with VCDD and helped to deliver a great new home for Gentronix and strong exit for the shareholders.”
Scantox acquires Gentronix, a UK based genetic toxicology CRO
Article
Acquisition of Workdry International by Arcus I...
A Hampshire-based group which specialises in water handling and treatment equipment has been acquired by Arcus Infrastructure Partners in a deal supported by...